DK0939590T3 - Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener - Google Patents
Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegenerInfo
- Publication number
- DK0939590T3 DK0939590T3 DK97942543T DK97942543T DK0939590T3 DK 0939590 T3 DK0939590 T3 DK 0939590T3 DK 97942543 T DK97942543 T DK 97942543T DK 97942543 T DK97942543 T DK 97942543T DK 0939590 T3 DK0939590 T3 DK 0939590T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- administration
- nucleic acid
- gene therapy
- cell genes
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 238000001415 gene therapy Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 1
- 230000010307 cell transformation Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/717,084 US6225290B1 (en) | 1996-09-19 | 1996-09-19 | Systemic gene therapy by intestinal cell transformation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0939590T3 true DK0939590T3 (da) | 2006-07-24 |
Family
ID=24880656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97942543T DK0939590T3 (da) | 1996-09-19 | 1997-09-18 | Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener |
Country Status (10)
Country | Link |
---|---|
US (4) | US6225290B1 (ja) |
EP (1) | EP0939590B1 (ja) |
JP (1) | JP2001502303A (ja) |
AT (1) | ATE320186T1 (ja) |
AU (1) | AU729457B2 (ja) |
CA (1) | CA2264744A1 (ja) |
DE (1) | DE69735496T2 (ja) |
DK (1) | DK0939590T3 (ja) |
ES (1) | ES2256896T3 (ja) |
WO (1) | WO1998011779A1 (ja) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
US7749215B1 (en) * | 1998-02-05 | 2010-07-06 | Biosense, Inc. | Intracardiac cell delivery and cell transplantation |
CA2323776C (en) | 1998-03-19 | 2010-04-27 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
BRPI9908967B1 (pt) * | 1998-03-20 | 2017-05-30 | Benitec Australia Ltd | processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta |
CA2324650A1 (en) * | 1998-05-06 | 1999-11-11 | Paul F. Russell | Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate |
JPH11335269A (ja) | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
EP1889914A1 (en) * | 1999-02-19 | 2008-02-20 | Engene, Inc. | Compositions for gene therapy of diabetes |
US6503887B1 (en) * | 1999-02-19 | 2003-01-07 | Matthew During | Peroral gene therapy of diabetes and obesity |
EP1161451A4 (en) | 1999-02-26 | 2006-05-17 | Human Genome Sciences Inc | HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE |
AU780754B2 (en) * | 1999-03-04 | 2005-04-14 | Revivicor Inc | Genetic modification of somatic cells and uses thereof |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US6953658B2 (en) | 2000-03-09 | 2005-10-11 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer |
CN102151337B (zh) * | 2000-03-13 | 2014-03-12 | 恩根尼公司 | 调节消化道蛋白表达的组合物和方法 |
EP2345742B1 (en) * | 2000-03-30 | 2014-06-11 | The Whitehead Institute for Biomedical Research | RNA sequence-specific mediators of RNA interference |
CA2405709A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB0010630D0 (en) * | 2000-05-04 | 2000-06-21 | Univ Wales Medicine | Sequence |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
AU2001271621A1 (en) | 2000-06-28 | 2002-01-08 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
ES2728168T3 (es) * | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Moléculas pequeñas de ARN que median en la interferencia de ARN |
US20020151068A1 (en) * | 2001-01-03 | 2002-10-17 | Board Of Regents, The University Of Texas System | Compositions and methods for the diagnosis and treatment of organophosphate toxicity |
CN1564826A (zh) | 2001-02-09 | 2005-01-12 | 人类基因组科学公司 | 人类g蛋白趋化因子受体(ccr5)hdgnr10 |
WO2002080852A2 (en) * | 2001-04-04 | 2002-10-17 | Digital Gene Technologies, Inc. | Genes expressed in intestinal epithelium and peyer's patch m cells |
KR20030093316A (ko) | 2001-04-13 | 2003-12-06 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 혈관 내피 성장 인자 2 |
WO2002083080A2 (en) * | 2001-04-17 | 2002-10-24 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
KR20030022094A (ko) * | 2001-05-24 | 2003-03-15 | (주)휴먼디엔에이테크놀로지 | 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체 |
WO2003060066A2 (en) * | 2001-11-07 | 2003-07-24 | Musc Foundation For Research Development | Nucleic acid delivery and expression |
US20030135195A1 (en) * | 2002-01-16 | 2003-07-17 | Oscar Jimenez | Highly lubricious hydrophilic coating utilizing dendrimers |
US7303871B2 (en) | 2002-02-14 | 2007-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
EP1490520A4 (en) * | 2002-03-12 | 2006-06-07 | Surface Logix Inc | TEST APPARATUS ANALYZING THE ABSORPTION, METABOLISM, PERMEABILITY AND / OR TOXICITY OF A CANDIDATE COMPOUND |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
AU2003273206B2 (en) * | 2002-05-31 | 2009-08-20 | Children's Hospital Medical Center | Method, composition and kit for antigenic binding of Norwalk-Like viruses |
US7977098B2 (en) | 2002-05-31 | 2011-07-12 | Children's Hospital Medical Center | Antigenic binding patterns of norovirus to human histo-blood group antigens |
US20040016013A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
US20040014698A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
US20040014704A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent induces tolerance |
EA008222B1 (ru) * | 2002-10-24 | 2007-04-27 | Байоджен Айдек Ма Инк. | Высокоэкспрессирующий локусный вектор, полученный на основе локуса гена тяжелой цепи ферритина |
US20050026859A1 (en) * | 2002-11-12 | 2005-02-03 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
WO2005032574A1 (en) * | 2003-10-03 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway |
US20050208032A1 (en) * | 2004-01-16 | 2005-09-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
EP1969009A4 (en) * | 2005-12-20 | 2009-07-22 | Arana Therapeutics Ltd | CHIMERIC ANTIBODIES AT PRIMATE PARTIAL BINDING REGIONS OF THE NEW WORLD |
WO2008020318A2 (en) * | 2006-03-30 | 2008-02-21 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
US20100310522A1 (en) * | 2007-11-26 | 2010-12-09 | Plant Bioscience Limited | Novel Polypeptides Having Endolysin Activity and Uses Thereof |
WO2009149191A2 (en) | 2008-06-03 | 2009-12-10 | University Of Rochester | Methods of treating inflammatory intestinal disease and managing symptoms thereof |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
US20100068153A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
US20100068283A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex VIVO modifiable particle or polymeric material medicament carrier |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
US20100068152A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable particle or polymeric based final dosage form |
GB0908949D0 (en) | 2009-05-26 | 2009-07-01 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
CN107043408B (zh) | 2009-06-09 | 2021-02-09 | 儿童医院医疗中心 | 抗原-诺罗病毒p-结构域单体和二聚体,抗原-诺罗病毒p-粒子分子,及其制备和应用方法 |
US9321803B2 (en) | 2013-07-12 | 2016-04-26 | Children's Hospital Medical Center | Compositions and methods for inhibiting norovirus infection |
AU2015241422B2 (en) | 2014-04-01 | 2020-12-03 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
US20160160229A1 (en) * | 2014-12-09 | 2016-06-09 | THC Farmaceuticals, Inc. | Methods of producing antibody-rich cannabis and honeysuckle plants |
CN110381991B (zh) | 2017-03-28 | 2024-04-09 | 儿童医院医学中心 | 诺如病毒s颗粒类疫苗及其制备和使用方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US5997859A (en) * | 1988-03-21 | 1999-12-07 | Chiron Corporation | Method for treating a metastatic carcinoma using a conditionally lethal gene |
EP0445227A4 (en) | 1988-11-23 | 1991-12-27 | The Regents Of The University Of California | Position-specific insertion vectors and method of using same |
DE69032284T2 (de) | 1989-03-21 | 1998-10-08 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
ATE157012T1 (de) | 1989-11-03 | 1997-09-15 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
AU3972893A (en) * | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
DE69333921T2 (de) * | 1992-12-31 | 2006-08-10 | Dana-Farber Cancer Institute, Inc., Boston | "enhancer" sequenz zur modulation der expression in epithelialzellen |
SG54115A1 (en) | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
EP0710288B1 (en) | 1993-06-10 | 2006-04-05 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
US5681744A (en) * | 1995-03-17 | 1997-10-28 | Greenstein; Robert J. | Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
WO1996040081A2 (en) | 1995-06-07 | 1996-12-19 | Alza Corporation | Oral delivery of gene constructs |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
-
1996
- 1996-09-19 US US08/717,084 patent/US6225290B1/en not_active Expired - Lifetime
-
1997
- 1997-09-18 JP JP10514853A patent/JP2001502303A/ja not_active Ceased
- 1997-09-18 DK DK97942543T patent/DK0939590T3/da active
- 1997-09-18 ES ES97942543T patent/ES2256896T3/es not_active Expired - Lifetime
- 1997-09-18 WO PCT/US1997/016523 patent/WO1998011779A1/en active IP Right Grant
- 1997-09-18 CA CA002264744A patent/CA2264744A1/en not_active Abandoned
- 1997-09-18 US US09/254,988 patent/US6258789B1/en not_active Expired - Lifetime
- 1997-09-18 DE DE69735496T patent/DE69735496T2/de not_active Expired - Fee Related
- 1997-09-18 AT AT97942543T patent/ATE320186T1/de not_active IP Right Cessation
- 1997-09-18 AU AU44221/97A patent/AU729457B2/en not_active Ceased
- 1997-09-18 EP EP97942543A patent/EP0939590B1/en not_active Expired - Lifetime
-
2001
- 2001-03-16 US US09/811,323 patent/US6831070B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 US US10/911,082 patent/US20050026863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001502303A (ja) | 2001-02-20 |
EP0939590A1 (en) | 1999-09-08 |
EP0939590B1 (en) | 2006-03-15 |
US6831070B2 (en) | 2004-12-14 |
US6258789B1 (en) | 2001-07-10 |
US20020039574A1 (en) | 2002-04-04 |
ES2256896T3 (es) | 2006-07-16 |
ATE320186T1 (de) | 2006-04-15 |
AU4422197A (en) | 1998-04-14 |
WO1998011779A1 (en) | 1998-03-26 |
DE69735496D1 (de) | 2006-05-11 |
CA2264744A1 (en) | 1998-03-26 |
US20050026863A1 (en) | 2005-02-03 |
EP0939590A4 (en) | 2002-09-04 |
DE69735496T2 (de) | 2006-09-21 |
AU729457B2 (en) | 2001-02-01 |
US6225290B1 (en) | 2001-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0939590T3 (da) | Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener | |
US5821235A (en) | Gene therapy using the intestine | |
US6747014B2 (en) | Compositions and methods for non-parenteral delivery of oligonucleotides | |
Cotti et al. | Healing of apical periodontitis in patients with inflammatory bowel diseases and under anti–tumor necrosis factor alpha therapy | |
JP2003525912A (ja) | 遺伝子送達用核酸製剤および使用方法 | |
DE69914932D1 (de) | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis | |
JPH11502413A (ja) | 分泌腺発現による遺伝子治療 | |
ATE327326T1 (de) | Fhit proteine und nukleinsäuren sowie darauf basierende verfahren | |
CA2227871A1 (en) | Mucosal delivery of polynucleotides | |
HUP9800028A2 (hu) | Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének | |
EA005496B1 (ru) | Растворимый гетеродимерный рецептор цитокина | |
Islamov et al. | Epidural stimulation combined with triple gene therapy for spinal cord injury treatment | |
US8946178B2 (en) | Compositions and methods for treatment of pouchitis | |
CN102462837A (zh) | 抗炎组合物 | |
Paap et al. | Total recall: intestinal TRM cells in health and disease | |
DE60036105D1 (de) | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs | |
HUP0002913A2 (hu) | Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára | |
Baum et al. | The mouth is a gateway to the body: gene therapy in 21st century dental practice | |
Culliton | Designing Cells to Deliver Drugs: As technical roadblocks slow some approaches to gene therapy, new avenues may lead to treatments for disorders including AIDS, cancer, heart disease, and emphysema | |
CN108685850A (zh) | 模块化组装的组合生物药物联合递送系统及应用 | |
Zhu et al. | Optimization of lipid nanoparticles for gene editing of the liver via intraduodenal delivery | |
Han et al. | Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by inhibiting honeycomb cyst and alveoli interstitium remodeling | |
Morikawa et al. | Impaired G‐CSF production at post‐transcriptional level in a patient with chronic idiopathic neutropenia | |
CN116173218B (zh) | 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途 | |
EP4022039B1 (en) | Activated mesenchymal stem cells for use in treating limb ischemia |